The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing
owing to increased longevity of the general population and the availability of effective …

Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease
with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a …

Importance Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary
markedly between Denmark and Sweden. The difference in the association of these national …

Objective To perform a meta-analysis of randomized, blinded, multiple sclerosis (MS) clinical
trials, to test the hypothesis that efficacy of immunomodulatory disease-modifying therapies …

Importance No current therapy for relapsing-remitting multiple sclerosis (MS) results in
significant reversal of disability. Objective To determine the association of nonmyeloablative …

Importance Low serum 25-hydroxyvitamin D (25 [OH] D) levels are associated with an
increased risk of multiple sclerosis (MS) as well as with increased disease activity and rate …

See Gaudioso and Naismith (doi: 10. 1093/brain/awaa295) for a scientific commentary on
this article. In an Italian registry study, Amato et al. provide evidence that sustained exposure …

The sphingosine-1-phosphate (S1P) receptor signaling system has biological and medical
importance and is the first lipid G protein–coupled receptor (GPCR) structure to be solved to …

Multiple sclerosis (MS), an inflammatory demyelinating and neurodegenerative disease of
the central nervous system, usually begins between the ages of 20 and 49 years, though in …

Abstract Sphingosine 1-phosphate (S1P) signaling regulates lymphocyte egress from
lymphoid organs into systemic circulation. The sphingosine phosphate receptor 1 (S1P1) …